Phaseline

Companies › Atavistik Bio

Atavistik Bio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Hematology, Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ATV-1601
AKT1 E17K inhibitor
AKT1Phase 1Hereditary Hemorrhagic Telangiectasia (HHT); Advanced Solid TumorsDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07601425ATV-1601Phase 1Hereditary Hemorrhagic Telangiectasia (HHT)HematologyDec 2027
NCT07038369ATV-1601Phase 1Advanced Solid TumorsOncologyAug 2028

Targets

AKT1 (1)

Companies with the same targets

AstraZeneca Merck & Co. (MSD) Roche Laekna Alterome Therapeutics Zhejiang Haichang Biotech

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.